Sanofi receives US green light for Blueprint Medicines buyout
Sanofi’s acquisition of Blueprint Medicines for about $9.5 billion has received clearance from US antitrust authorities. The waiting period under the Hart-Scott-Rodino Act expired on July 9, according to a securities...To view the full article, register now.
Already a subscriber? Click here to view full article